A$0.061 -0.0 -3.2%
Last Trade - 15/10/21
| Market Cap | £6.66m |
| Enterprise Value | £3.79m |
| Revenue | £3.15m |
| Position in Universe | 1730th / 1953 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.39 | 4.72 | 5.76 | 7.47 | 7.34 | 5.82 | 30.3 | 36.1 | +11.4% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cellmid Limited is an Australia-based health and beauty-tech business company. The Company is specialized in developing anti-aging solutions. The Company operates through two segments: Diagnostics and Consumer Health. The Company is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. It is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. It has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.
| Last Annual | June 30th, 2021 |
| Last Interim | June 30th, 2021 |
| Incorporated | October 8, 2004 |
| Public Since | December 9, 2005 |
| No. of Shareholders: | 2,280 |
| No. of Employees: | n/a |
| Sector | Consumer Defensives |
| Industry | Personal & Household Products & Services |
| Index | |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 201,386,655 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | SE 204 L 2 55 Clarence Street, SYDNEY, 2000, Australia |
| Web | http://www.cellmid.com.au/ |
| Phone | +61 2 92216830 |
| Contact | () |
| Auditors | Pitcher Partners |
As of 15/10/21, shares in Cellmid are trading at A$0.061, giving the company a market capitalisation of £6.66m. This share price information is delayed by 15 minutes.
Shares in Cellmid are currently trading at A$0.061 and the price has moved by -37.58% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cellmid price has moved by -47.83% over the past year.
Of the analysts with advisory recommendations for Cellmid, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cellmid is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Cellmid is scheduled to issue upcoming financial results on the following dates:
Cellmid does not currently pay a dividend.
Cellmid does not currently pay a dividend.
Cellmid does not currently pay a dividend.
To buy shares in Cellmid you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Cellmid are currently trading at A$0.061, giving the company a market capitalisation of £6.66m.
Here are the trading details for Cellmid:
Based on an overall assessment of its quality, value and momentum, Cellmid is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Cellmid are currently priced at A$0.061. At that level they are trading at 1.64% discount to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cellmid. Over the past six months, the relative strength of its shares against the market has been -20.21%. At the current price of A$0.061, shares in Cellmid are trading at -14.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Cellmid.
Cellmid's management team is headed by:
Here are the top five shareholders of Cellmid based on the size of their shareholding:
